[{"id":"a154e2c7-3e0a-4a08-9d78-f38920d834dd","acronym":"LYMFOR","url":"https://clinicaltrials.gov/study/NCT06125028","created_at":"2023-11-09T16:12:55.005Z","updated_at":"2024-07-02T16:34:59.106Z","phase":"Phase 3","brief_title":"[68Ga]Ga-PentixaFor-PET Imaging for Staging of Marginal Zone Lymphoma","source_id_and_acronym":"NCT06125028 - LYMFOR","lead_sponsor":"Pentixapharm AG","biomarkers":" CXCR4","pipe":" | ","alterations":" CXCR4 expression • CXCR4 positive","tags":["CXCR4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CXCR4 expression • CXCR4 positive"],"overall_status":"Recruiting","enrollment":" Enrollment 148","initiation":"Initiation: 06/01/2024","start_date":" 06/01/2024","primary_txt":" Primary completion: 06/15/2025","primary_completion_date":" 06/15/2025","study_txt":" Completion: 06/15/2025","study_completion_date":" 06/15/2025","last_update_posted":"2024-06-04"},{"id":"74a6310f-c8b8-42b2-9de4-5b6c003043bf","acronym":"","url":"https://clinicaltrials.gov/study/NCT06234319","created_at":"2024-02-01T01:21:24.801Z","updated_at":"2024-07-02T16:35:16.409Z","phase":"","brief_title":"CXCR4 PET/MRI Targeted Imaging for Grading Diagnosis, Molecular Typing, and Prognostic Evaluation of Brain Glioma","source_id_and_acronym":"NCT06234319","lead_sponsor":"Xiao Chen","biomarkers":" CXCR4 • CD34","pipe":" | ","alterations":" CXCR4 expression","tags":["CXCR4 • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CXCR4 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 02/15/2024","start_date":" 02/15/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-03-05"},{"id":"ec7f3f07-9bc3-4dd0-a1ea-5b794d106fef","acronym":"","url":"https://clinicaltrials.gov/study/NCT06086327","created_at":"2023-10-17T15:12:41.211Z","updated_at":"2024-07-02T16:35:33.342Z","phase":"Phase 1","brief_title":"Application of 68Ga-Pentixafor PET/CT for Thymoma","source_id_and_acronym":"NCT06086327","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" CXCR4","pipe":" | ","alterations":" CXCR4 expression","tags":["CXCR4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CXCR4 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 06/22/2023","start_date":" 06/22/2023","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-10-17"},{"id":"4afd349a-0b45-4747-93b5-fe5a5bd0af0b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05364177","created_at":"2022-05-06T18:55:09.031Z","updated_at":"2024-07-02T16:36:10.832Z","phase":"Phase 1","brief_title":"68Ga-pentixather and 68Ga-pentixafor PET/CT in Multiple Myeloma","source_id_and_acronym":"NCT05364177","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" CXCR4","pipe":" | ","alterations":" CXCR4 expression","tags":["CXCR4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CXCR4 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 08/11/2021","start_date":" 08/11/2021","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2022-05-06"},{"id":"ef305389-9686-430a-961c-050929e8a0a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02807272","created_at":"2021-01-18T13:46:04.937Z","updated_at":"2024-07-02T16:36:30.264Z","phase":"Phase 2","brief_title":"Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia","source_id_and_acronym":"NCT02807272","lead_sponsor":"Kura Oncology, Inc.","biomarkers":" KRAS • NRAS • CXCR4 • CXCR2","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type • NRAS wild-type • CXCR4 expression","tags":["KRAS • NRAS • CXCR4 • CXCR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type • NRAS wild-type • CXCR4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zarnestra (tipifarnib)"],"overall_status":"Completed","enrollment":" Enrollment 45","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 12/14/2020","primary_completion_date":" 12/14/2020","study_txt":" Completion: 12/14/2020","study_completion_date":" 12/14/2020","last_update_posted":"2021-05-14"},{"id":"baa0ccb2-bd1a-47d5-a999-d77ee373a8b3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03436342","created_at":"2021-01-18T16:57:29.307Z","updated_at":"2024-07-02T16:36:52.044Z","phase":"Phase 1","brief_title":"Chemokine Receptor CXCR4-targeting Molecular Imaging for Metabolic Characterization of Multiple Myeloma and Lymphoma","source_id_and_acronym":"NCT03436342","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" CXCR4","pipe":" | ","alterations":" CXCR4 expression","tags":["CXCR4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CXCR4 expression"],"overall_status":"Unknown status","enrollment":" Enrollment 100","initiation":"Initiation: 06/01/2019","start_date":" 06/01/2019","primary_txt":" Primary completion: 03/01/2020","primary_completion_date":" 03/01/2020","study_txt":" Completion: 12/01/2020","study_completion_date":" 12/01/2020","last_update_posted":"2019-12-27"},{"id":"5196c7bf-5bf9-4cf9-8711-f852ccafb593","acronym":"","url":"https://clinicaltrials.gov/study/NCT01319864","created_at":"2021-01-18T05:22:22.912Z","updated_at":"2024-07-02T16:37:07.140Z","phase":"Phase 1","brief_title":"POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients","source_id_and_acronym":"NCT01319864","lead_sponsor":"Seattle Children's Hospital","biomarkers":" CXCR4","pipe":" | ","alterations":" CXCR4 expression","tags":["CXCR4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CXCR4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • plerixafor"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 03/01/2011","start_date":" 03/01/2011","primary_txt":" Primary completion: 06/28/2013","primary_completion_date":" 06/28/2013","study_txt":" Completion: 06/28/2016","study_completion_date":" 06/28/2016","last_update_posted":"2018-09-07"}]